Genomic Landscape of Acquired Resistance to first-line (1L) anti-EGFR treatment in Metastatic Colorectal Cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Grupo TTD > Comunicaciones > Genomic Landscape of Acquired Resistance to first-line (1L) anti-EGFR treatment in Metastatic Colorectal Cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
